Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

GlobeNewswire December 1, 2020

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

GlobeNewswire November 24, 2020

The StockTalk Cannabis Report: Nov. 20, 2020

Dave Jackson November 20, 2020

An Emerging Opportunity in Psychedelics

Stockhouse Editorial November 19, 2020

PharmaTher & Revive Therapeutics Team-Up to Investigate Psychedelic Cancer Treatment Therapies

Stockhouse Editorial November 18, 2020

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

GlobeNewswire November 18, 2020

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI(TM) Psychedelic Discovery AI Platform

GlobeNewswire November 18, 2020

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

GlobeNewswire November 16, 2020

Prolific Parkinson's Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

GlobeNewswire November 11, 2020

Leading Parkinson's Researcher Dr. Robert A. Hauser Joins Pharmather as Scientific Advisor

GlobeNewswire October 29, 2020

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain

GlobeNewswire October 27, 2020

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

GlobeNewswire October 22, 2020

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease

GlobeNewswire October 20, 2020

Pharmather Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the Treatment of Parkinson's Disease

GlobeNewswire October 15, 2020

Pharmather Engages Clarus Securities As Capital Markets Advisor

GlobeNewswire October 13, 2020

CSE Bulletin: New Listing - Newscope Capital Corporation (PHRM)

Newsfile October 8, 2020

Newscope Capital (d/b/a Pharmather) Announces Listing on the Canadian Securities Exchange

GlobeNewswire October 8, 2020